Comparative Study of Umeclidinium/Vilanterol (UMEC/VI) in a Fixed Dose Combination With Indacaterol Plus Tiotropium

PHASE3CompletedINTERVENTIONAL
Enrollment

967

Participants

Timeline

Start Date

October 15, 2014

Primary Completion Date

May 4, 2015

Study Completion Date

May 4, 2015

Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
DRUG

UMEC/VI

ELLIPTA DPI will be supplied with 30 doses (2 strips with 30 blisters per strip) where first strip contains Umeclidinium bromide (unit dose strengths 62.5 mcg per blister) blended with lactose monohydrate and magnesium stearate 0.6% weight/weight (w/w) of total drug product and second strip contains Vilanterol (unit dose strengths 25 mcg per blister) blended with lactose monohydrate and magnesium stearate 1.0% w/w of total drug product

DRUG

UMEC/VI matching placebo

ELLIPTA DPI will be supplied with 30 doses (2 strips with 30 blisters per strip) where first strip contains lactose monohydrate and magnesium stearate 0.6% w/w of total drug product and second strip contains lactose monohydrate and magnesium stearate 1.0% w/w of total drug product

DRUG

Tiotropium

Tiotropium (as bromide monohydrate) inhalation capsules 18 mcg per dose will be supplied along with HANDIHALER inhalers manufactured by Boehringer Ingelheim

DRUG

Tiotropium matching placebo

Tiotropium matching placebo capsules manufactured by GSK, will contain lactose and will be supplied along with HANDIHALER inhalers

DRUG

Indacaterol

Indacaterol inhalation capsules 150 mcg per dose will be supplied by GSK along with BREEZHALER inhalers manufactured by Novartis

DRUG

Indacaterol matching placebo

Indacaterol matching placebo capsules manufactured by GSK, will contain lactose and will be supplied along with BREEZHALER inhalers manufactured by Novartis

DRUG

Albuterol/salbutamol Metered Dose Inhaler (MDI)

Albuterol/salbutamol MDI or nebules for as needed use will be issued throughout the study. Albuterol/salbutamol will be sourced from local commercial stock. If not available locally, GSK will source centrally

Trial Locations (84)

2040

GSK Investigational Site, Budaörs

2100

GSK Investigational Site, Gödöllő

2660

GSK Investigational Site, Balassagyarmat

3800

GSK Investigational Site, Szikszó

4000

GSK Investigational Site, San Miguel de Tucumán

GSK Investigational Site, San Miguel de Tucumán

4032

GSK Investigational Site, Debrecen

4400

GSK Investigational Site, Nyíregyháza

5500

GSK Investigational Site, Mendoza

6722

GSK Investigational Site, Szeged

7600

GSK Investigational Site, Mar del Plata

7635

GSK Investigational Site, Pécs

10117

GSK Investigational Site, Tallinn

10138

GSK Investigational Site, Tallinn

10367

GSK Investigational Site, Berlin

10787

GSK Investigational Site, Berlin

12203

GSK Investigational Site, Berlin

15562

GSK Investigational Site, Rüdersdorf

19055

GSK Investigational Site, Schwerin

20253

GSK Investigational Site, Hamburg

20354

GSK Investigational Site, Hamburg

21049

GSK Investigational Site, Tradate (VA)

22299

GSK Investigational Site, Hamburg

28100

GSK Investigational Site, Novara

29121

GSK Investigational Site, Piacenza

33170

GSK Investigational Site, Pordenone

38610

GSK Investigational Site, Gières

39112

GSK Investigational Site, Magdeburg

44277

GSK Investigational Site, Nantes

46100

GSK Investigational Site, Mantova

51092

GSK Investigational Site, Reims

60389

GSK Investigational Site, Frankfurt am Main

60596

GSK Investigational Site, Frankfurt am Main

65013

GSK Investigational Site, Tarbes

66000

GSK Investigational Site, Perpignan

67091

GSK Investigational Site, Strasbourg

90502

GSK Investigational Site, Haapsalu

125284

GSK Investigational Site, Moscow

153000

GSK Investigational Site, Arkhangelsk

194356

GSK Investigational Site, Saint Petersburg

195030

GSK Investigational Site, Saint Petesburg

198216

GSK Investigational Site, Saint Petersburg

240564

GSK Investigational Site, Râmnicu Vâlcea

300310

GSK Investigational Site, Timișoara

300465

GSK Investigational Site, Timișoara

355017

GSK Investigational Site, Stavropol

400371

GSK Investigational Site, Cluj-Napoca

420015

GSK Investigational Site, Kazan'

432063

GSK Investigational Site, Ulyanovsk

460040

GSK Investigational Site, Orenburg

614068

GSK Investigational Site, Perm

620039

GSK Investigational Site, Yekaterinburg

620149

GSK Investigational Site, Yekaterinburg

634063

GSK Investigational Site, Tomsk

644112

GSK Investigational Site, Omsk

664079

GSK Investigational Site, Irkutsk

900002

GSK Investigational Site, Constanța

7500692

GSK Investigational Site, Santiago

7500698

GSK Investigational Site, Santiago

7510186

GSK Investigational Site, Santiago

8207257

GSK Investigational Site, Puente Alto - Santiago

C1424BSF

GSK Investigational Site, Buenos Aires

C1425BEN

GSK Investigational Site, Buenos Aires

C1426ABP

GSK Investigational Site, Buenos Aires

M5500CCG

GSK Investigational Site, Mendoza

Lima 27

GSK Investigational Site, Lima

Lima 14

GSK Investigational Site, Lima

Lima 18

GSK Investigational Site, Lima

Lima 1

GSK Investigational Site, Lima

Lima 32

GSK Investigational Site, Lima

82-300

GSK Investigational Site, Elblag

31-024

GSK Investigational Site, Krakow

63-400

GSK Investigational Site, Ostrów Wielkopolski

41-940

GSK Investigational Site, Piekary Śląskie

81-741

GSK Investigational Site, Sopot

76-200

GSK Investigational Site, Słupsk

020125

GSK Investigational Site, Bucharest

050159

GSK Investigational Site, Bucharest

115 478

GSK Investigational Site, Moscow

972 01

GSK Investigational Site, Bojnice

066 01

GSK Investigational Site, Humenné

058 01

GSK Investigational Site, Poprad

052 01

GSK Investigational Site, Spišská Nová Ves

952 01

GSK Investigational Site, Vráble

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT02257385 - Comparative Study of Umeclidinium/Vilanterol (UMEC/VI) in a Fixed Dose Combination With Indacaterol Plus Tiotropium | Biotech Hunter | Biotech Hunter